Our in vivo experiments demonstrating activity of AN3661 against Toxoplasma infections in murine models of infection suggest a new avenue in toxoplasmosis drug discovery and should encourage new studies to evaluate the activity of this CPSF3 inhibitor and related compounds against slow‐growing bradyzoites in cysts, which are so far untreatable. Here, CPSF3 is linked to toxoplasmosis.